Striverdi Respimat Drug Interactions

Adrenergic agents: Concomitant administration of other adrenergic agents (alone or as part of combination therapy) may potentiate the adverse effects of STRIVERDI RESPIMAT.
Xanthine derivatives, steroids or diuretics: Concomitant treatment with xanthine derivatives, steroids, or non-potassium sparing diuretics may potentiate any hypokalemic effect of adrenergic agonists (see Precautions).
Beta-blockers: Beta-adrenergic blockers may weaken or antagonise the effect of STRIVERDI RESPIMAT. Therefore, STRIVERDI RESPIMAT should only be given together with beta-adrenergic blockers (including eye-drops) if there are compelling reasons for their use. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.
MAO Inhibitors and tricyclic antidepressants, QTc prolonging drugs: Monamine oxidase inhibitors or tricyclic antidepressants or other drugs known to prolong the QTc interval may potentiate the action of STRIVERDI RESPIMAT on the cardiovascular system.
Pharmacokinetic drug-drug interactions: No relevant effect on systemic exposure to olodaterol has been observed in drug-drug interaction studies with co-administration of fluconazole, used as model inhibitor of CYP2C9.
Co-administration of ketoconazole as potent P-gp and CYP inhibitor increased systemic exposure to olodaterol by approximately 70%. No dose adjustment is necessary.
Co-administration of olodaterol and tiotropium had no relevant effect on the systemic exposure to either of the two drugs.
In vitro investigations have shown that olodaterol does not inhibit CYP enzymes or drug transporters at the plasma concentrations achieved in clinical practice.